Extrapolation of enalapril efficacy from adults to children using pharmacokinetic/pharmacodynamic modelling. (10th August 2015)

• Record Type: Journal Article
• Authors: Kechagia, Irene‐Ariadne; Kalantzi, Lida; Dokoumetzidis, Aristides
• Is Part Of: Journal of pharmacy and pharmacology. Volume 67:Number 11(2015:Nov.)
• Page Start: 1537
• Page End: 1545
• Publication Date: 2015-08-10
• Subjects: Pharmacy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/jphp.12471
• Languages: English
• ISSNs: 0022-3573

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="jphp12471-sec-0001" sec-type="section"> <title>Objectives</title> <p>To extrapolate enalapril efficacy to children 0–6 years old, a pharmacokinetic/pharmacodynamic (PKPD) model was built using literature data, with blood pressure as the PD endpoint.</p> </sec> <sec id="jphp12471-sec-0002" sec-type="section"> <title>Methods</title> <p>A PK model of enalapril was developed from literature paediatric data up to 16 years old. A PD model of enalapril was fitted to adult literature response vs time data with various doses. The final PKPD model was validated with literature paediatric efficacy observations (diastolic blood pressure (DBP) drop after 2 weeks of treatment) in children of age 6 years and higher. The model was used to predict enalapril efficacy for ages 0–6 years.</p> </sec> <sec id="jphp12471-sec-0003" sec-type="section"> <title>Key findings</title> <p>A two‐compartment PK model was chosen with weight, reflecting indirectly age as a covariate on clearance and central volume. An indirect link PD model was chosen to describe drug effect. External validation of the model's capability to predict efficacy in children was successful. Enalapril efficacy was extrapolated to ages 1–11 months and 1–6 years finding the mean DBP drop 11.2 and 11.79 mmHg, respectively.</p> </sec> <sec id="jphp12471-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Mathematical modelling was used to extrapolate enalapril efficacy to young children to support a paediatric investigation plan targeting a paediatric‐use marketing authorization application.</p> </sec> </abstract>